CWP
ABUS icon

Cyndeo Wealth Partners’s Arbutus Biopharma ABUS Stock Holding History

Cyndeo Wealth Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$48.1K – 479
2025
Q4 		$48.1K Hold
10,000
– – ﹤0.01% 476
2025
Q3 		$45.4K Hold
10,000
– – ﹤0.01% 474
2025
Q2 		$30.9K Hold
10,000
– – ﹤0.01% 464
2025
Q1 		$34.9K Buy
+10,000
New +$33.3K ﹤0.01% 447

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Cyndeo Wealth Partners's ABUS Position: Q1 2026 in Review

Cyndeo Wealth Partners sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 10,000 shares — an estimated $48.1K sold.

Cyndeo Wealth Partners first reported a position in ABUS in Q1 2025 and held it in 4 quarters. The position peaked at $48.1K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Cyndeo Wealth Partners reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Cyndeo Wealth Partners sold 10,000 Arbutus Biopharma shares in Q1 2026, an estimated $48.1K.
  • Cyndeo Wealth Partners first reported a position in Arbutus Biopharma in Q1 2025 and held it in 4 quarters.
  • Cyndeo Wealth Partners's Arbutus Biopharma position peaked at $48.1K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Cyndeo Wealth Partners's 13F filing for Q1 2026, filed 13 Apr 2026.